可切除dMMR/MSI-H癌症的生物学和不断变化的管理:当前状况和未来前景

Tokiyoshi Tanegashima1, Masaki Shiota2, Kayo Toyosaki3

  • 1Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.

概括

免疫检查点抑制剂对不匹配修复缺陷 (dMMR) 或微卫星不稳定性高 (MSI-H) 瘤有希望,可使器官保存. 需要进一步的研究来优化患者选择,并了解长期的结果.

相关概念视频

Mismatch Repair01:36

Mismatch Repair

Overview
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...